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1144.e1 The Journal of Thoracic and CaBackground: Hyperglycemia is commonly present in the perioperative period in
patients undergoing cardiac surgery, even during administration of insulin. A direct
relationship between postoperative hyperglycemia and mortality has been estab-
lished in diabetic patients undergoing cardiac surgery. However, this relationship
might be confounded because patients with poor outcome receive more glucogenic
drugs postoperatively. We assessed the influence of hyperglycemia (highest glucose
level) during cardiopulmonary bypass on perioperative morbidity and mortality in
diabetic and nondiabetic patients.
Methods: We performed a multivariate logistic regression analysis on all diabetic
(n  1579) and nondiabetic (n  4701) patients undergoing cardiac surgery at the
Toronto General Hospital between 1999 and 2001. Boluses of insulin were given
during cardiopulmonary bypass when the glucose level exceeded 15 mmol/L, when
the serum potassium level exceeded 6.0 mmol/L, or both.
Results: Overall mortality was 1.8% (n  115). A high glucose level during
cardiopulmonary bypass was an independent predictor of mortality in both diabetic
(odds ratio, 1.20; confidence interval, 1.08-1.32) and nondiabetic (odds ratio, 1.12;
confidence interval, 1.06-1.19; per millimole per liter increase in glucose) patients.
A high glucose level during cardiopulmonary bypass was also an independent
predictor of all major adverse events in both patient groups (odds ratio, 1.06;
confidence interval, 1.03-1.09). A high glucose level was not closely related to
cardiopulmonary bypass (r  0.3) or aortic crossclamp times (r  0.4).
Conclusions: A high peak serum glucose level during cardiopulmonary bypass is an
independent risk factor for death and morbidity in diabetic patients and unexpect-
edly also in nondiabetic patients.
Hyperglycemia is common during and after cardiac surgery in both diabeticand nondiabetic patients. Its treatment requires increased dosages of insu-lin, and even extremely high dosages might sometimes not be successful in
establishing euglycemia.1,2 To date, perioperative hyperglycemia has not been
treated aggressively, mainly because it has been considered harmless, and some
evidence has even suggested beneficial effects.1,3 However, recent investigations
suggest that postoperative hyperglycemia is directly related to mortality in patients
with diabetes mellitus (DM).4,5 In addition, avoiding postoperative hyperglycemia
improves outcomes in patients with prolonged intensive care unit (ICU) stays6 and
in patients with DM.5
Conclusions from previous studies regarding the effect of hyperglycemia on
outcome after cardiac surgery have to be drawn with caution for 3 reasons. First, the
degree of postoperative hyperglycemia in diabetic patients might be a reflection of
the severity of the patients’ DM, which might be a marker for increased comor-
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with a complicated postoperative course are more likely to
receive glucogenic drugs (eg, epinephrine) than those with
an uncomplicated course. Third, insulin, which was used to
treat hyperglycemia in these studies, might have a direct
effect on outcome independent of its effects on serum
glucose levels.1,8 It is therefore still unclear whether peri-
operative hyperglycemia has a direct effect on adverse
events and mortality in cardiac surgery, particularly in non-
diabetic patients.
The purpose of this study was to determine the influence
of peak hyperglycemia (ie, highest measured glucose level
during cardiopulmonary bypass [CPB]) on perioperative
morbidity and mortality in patients undergoing cardiac sur-
gery. In addition, we attempted to determine whether this
relationship is the same in both diabetic and nondiabetic
patients. We chose the highest glucose level during CPB as
our independent variable because it likely reflects a degree
of perioperative insulin resistance and is not influenced by
the administration of post-CPB glucogenic drugs.
Methods
We reviewed data on all patients undergoing cardiac surgery at our
institution from January 1999 through December 2001 (n 6280).
This retrospective study was approved by the institutional research
ethics board. Patients undergoing any cardiac procedure that re-
quired CPB were included: 4190 underwent isolated coronary
bypass grafting, 1224 underwent valvular procedures with or with-
out concomitant coronary bypass, and 866 underwent other pro-
cedures, including heart transplantation, aneurysmectomy, replace-
ment of the aorta, and adult congenital procedures. Patients
undergoing off-pump coronary bypass surgery were excluded. The
distribution of operative procedures was similar for diabetic and
nondiabetic patients.
Patients were divided into 2 groups: those with an established
diagnosis of DM (diabetic subjects, n  1579) and those without
evidence of DM (nondiabetic subjects, n  4701). The diabetic
group included patients with type 1 and type 2 DM, and patients
with type 2 diabetes were included regardless of whether they were
being treated with diet, oral hypoglycemics, and/or insulin. All
patients were assessed preoperatively by their general practitioner
and by a cardiologist. Several serum glucose measurements were
performed in this process. The likelihood of missing the diagnosis
of DM was therefore small.
Perioperative management was the same for all patients. CPB
flow rates were maintained at between 2.0 and 2.5 L · min1 · m2,
and mean arterial pressure was kept at greater than 70 mm Hg at
all times. Hematocrit was kept at greater than 20%, and mild
hypothermia (34°C) was used during CPB. The CPB priming
circuit was free of glucose. Cardioplegia consisted of oxygenated
blood mixed with crystalloid in an 8:1 ratio and was administered
cold and antegrade in the vast majority of patients, as described
previously.9 Glucose levels were determined on pump on average
every 15 minutes. Boluses of insulin were administered during
CPB when the glucose level exceeded 15 mmol/L (270 mg/dL),
when the serum potassium level exceeded 6.0 mmol/L, or both. In
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ications were held the morning of the operation. In their place,
patients received an intravenous solution of glucose (D5W) and
insulin that was adjusted according to subsequent glucose levels.
The infusion was continued through the perioperative period and
was discontinued when the patients were able to ingest adequate
amounts of food, usually 2 to 3 days postoperatively.
Data Source
Data were gathered on all patients, including preoperative, intra-
operative, and postoperative variables, and were entered into our
computerized database by a full-time database manager. We have
maintained our institutional database for approximately 15 years,
and quality assurance checks have consistently revealed a missing
data rate of less than 2% and an error rate of less than 2%. Patients
who were missing serum glucose levels (n  135) were excluded
from the analysis. All adverse outcomes were recorded by our
database manager, using clinical criteria that have been previously
described.9 Adverse cardiac events were defined as a composite
end point of low output syndrome and acute myocardial infarction.
All adverse events were defined as a composite end point of death,
stroke, deep sternal wound infection, low output syndrome, and
acute myocardial infarction. All deaths were recorded as in-
hospital deaths. Serum glucose levels were measured with a Rapid-
point 400 (Bayer Healthcare, Philadelphia, Pa), and the highest and
lowest levels during CPB were entered into our database. For
values of 25 mmol/L or greater, the analyzer displayed a value of
25 mmol/L (450 mg/dL).
Analysis
Categoric data are expressed as percentages, and continuous data
are expressed as means  standard deviations throughout the
article. SAS version 8.2 software (SAS Institute, Cary, NC) was
used for all statistical analyses. Categoric data were analyzed
univariately by means of 2 or Fisher exact tests, and continuous
data were analyzed by using Student unpaired t tests or Wilcoxon
rank sum tests where appropriate. Stepwise multivariate logistic
regression analysis was used to calculate risk-adjusted odds ratios
(ORs) and to determine the independent predictors of each out-
come of interest. For a complete list of variables assessed in the
logistic regression models, please see the Appendix E1. All vari-
ables suggested by the univariate analysis (P  .25) or those
judged to be clinically important were entered into the logistic
regression models. Model discrimination was evaluated by using
the area under the receiver operating characteristic curve, and
model precision was evaluated by using the Hosmer-Lemeshow
goodness-of-fit statistic, as previously described.9
Results
Tables 1 and 2 show the prevalence of risk factors in
nondiabetic (Table 1) and diabetic (Table 2) patients in-
cluded in this study. The tables distinguish between those
patients with peak serum glucose levels during CPB of less
than and greater than 20 mmol/L (360 mg/dL). The value of
20 mmol/L was chosen on the basis of the inflection point in
the relationship between peak serum glucose level during
CPB and mortality (Figure 1). Among nondiabetic patients
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cantly more preoperative risk factors than patients with peak
glucose levels of less than 20 mmol/L. The percentages of
hypertension, preoperative myocardial infarction, triple-
vessel disease, and peripheral vascular disease, as well as
low ejection fraction, were higher in the diabetic than in the
nondiabetic patients (compare Tables 1 and 2, all P  .05).
In contrast, the risk profiles of diabetic patients with peak
glucose levels of greater than or less than 20 mmol/L (360
mg/dL) were not different (Table 1). Inotropes were re-
quired to be weaned from CPB in 15.4% of diabetic and
12.5% of nondiabetic patients. The peak glucose levels of
these patients were not different from those of patients
coming off CPB without inotropes (diabetic/nondiabetic:
without inotropes, 16.0  3.82/13.8  3.61 mmol/L; with
inotropes, 16.3  4.25/14.9  4.16 mmol/L).
Figure 1 shows the in-hospital mortality of diabetic and
nondiabetic patients as a function of peak glucose level
during CPB. Although mortality was less than 2% when the
peak glucose level remained less than 20 mmol/L (360
TABLE 1. Prevalence of risk factors in nondiabetic
patients with peak intraoperative serum glucose levels
of greater than and less than 20 mmol/L (360 mg/dL)
Risk factor
Serum glucose level
<20 mmol/L
(n  4289)
>20 mmol/L
(n  314) P value
Age (y) 61  13 60  13 .7
Male sex 74% 67% .008
Hypertension 48% 48% .9
Preop MI 14% 14% .9
LV grade .04
1 46% 43%
2 36% 37%
3 16% 15%
4 2.5% 5.1%
Peripheral vascular disease 10% 11% .4
Congestive heart failure 20% 34% .001
Left main disease 15% 12% .12
Triple-vessel disease 51% 49% .4
Timing of operation .06
Elective 59% 56%
Same hospital stay 33% 32%
Urgent 5.4% 7.4%
Emergency 2.6% 4.8%
Cardiogenic shock 1.1% 3.2% .002
Renal failure 3.2% 6.1% .007
Redo CABG 3.3% 7.0% .001
Any redo 8.6% 17.5% .0001
Preop MI, Preoperative myocardial infarction; LV grade, preoperative
ejection fraction where grade 1 is greater than 60%, grade 2 is 40% to 59%,
grade 3 is 20% to 39%, and grade 4 is less than 20%; Redo CABG, previous
coronary artery bypass grafting; Any redo, any previous cardiac surgery.mg/dL), the incidence tripled when the peak glucose level
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mortality and hyperglycemia was identical for patients with
and without diabetes. Total mortality was 1.7% in nondia-
betic and 2.1% in diabetic patients (P  .4).
Tables 3 and 4 show the ORs for peak serum glucose
level as an independent predictor of adverse outcomes in
nondiabetic (Table 3) and diabetic (Table 4) patients. In
both patient populations, peak glucose level was an inde-
pendent predictor of death and all adverse events. For ad-
verse cardiac events, the ORs reached significance in non-
diabetic patients only. It is interesting to note that the ORs
of high glucose level were higher for mortality than for any
other adverse event. Other predictors of mortality in nondi-
abetic patients were (OR and 95% confidence intervals in
parentheses): age (1.03 per year; 1.01-1.05), female sex
TABLE 2. Prevalence of risk factors in diabetic patients
with peak intraoperative serum glucose levels of greater
than and less than 20 mmol/L (360 mg/dL)
Risk factor
Serum glucose level
<20 mmol/L
(n  1307)
>20 mmol/L
(n  235) P value
Age (y) 64  9 64  10 .6
Male sex 75% 67% .02
Hypertension 68% 66% .4
Preop MI 21% 18% .2
LV grade .002
1 37% 27%
2 39% 40%
3 21% 27%
4 3.5% 7.2%
Peripheral vascular disease 20% 18% .5
Congestive heart failure 20% 26% .04
Left main disease 18% 15% .4
Triple-vessel disease 75% 80% .11
Timing of the operation .19
Elective 51% 58%
Same hospital stay 41% 34%
Urgent 6.9% 6.8%
Emergency 1.2% 1.7%
Cardiogenic shock 2.1% 2.6% .6
Treatment of DM .005
Diet controlled 15.6% 8.1%
Oral hypoglycemics 64.5% 66.7%
Insulin 20% 25.2%
Renal failure 6.9% 6.4% .8
Redo CABG 3.1% 4.3% .4
Any redo 15% 20% .2
Preop MI, Preoperative myocardial infarction; LV grade, preoperative
ejection fraction where grade 1 is greater than 60%, grade 2 is 40% to 59%,
grade 3 is 20% to 39%, and grade 4 is less than 20%; DM, diabetes mellitus;
Redo CABG, previous coronary artery bypass grafting; Any redo, any
previous cardiac surgery.(1.96; 1.18-3.23), congestive heart failure (2.71; 1.54-4.75),
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vascular disease (2.32; 1.26-4.28), and emergency operation
(5.42; 2.89-10.20). For diabetic patients, other predictors of
mortality were congestive heart failure (3.45; 1.44-8.25),
renal failure (4.37; 1.73-11.1), and emergency operation
(8.92; 3.23-24.6). Cardiogenic shock, poor left ventricular
function, and redo operations (except redo coronary bypass
Figure 1. Peak glucose levels during cardiopulmonary bypass
(CPB) and operative mortality in diabetic (n  1579) and nondi-
abetic (n  4701) patients operated on at our institution between
January 1999 and December 2001. The numbers at the top of the
columns indicate the percentage of patients with peak glucose
levels in the respective range.
TABLE 3. Glucose as an independent predictor of outcome
in nondiabetic patients
Outcome variable
Odds
ratio
Lower
95% CI
Upper
95% CI P value
Mortality 1.12 1.06 1.19 .0001
Adverse cardiac
events
1.05 1.02 1.09 .0031
All adverse
events
1.06 1.03 1.09 .0001
Values represent odds ratios and confidence intervals for 1 mmol/L
changes in serum glucose levels. Adverse cardiac events: myocardial
infarction, low output syndrome, death. All adverse events: stroke, infec-
tion, myocardial infarction, low output syndrome, death. CI, Confidence
interval.
The Journal of Thoracic anin nondiabetic patients) were not significant risk factors for
mortality.
We attempted to determine whether there was a relation-
ship between peak glucose levels and CPB or aortic cross-
clamp times. Figure 2 is a plot of peak glucose versus CPB
time for nondiabetic patients. The Spearman correlation
coefficient (r) was 0.43 for nondiabetic and 0.35 for diabetic
patients. Similarly, the correlation coefficient for peak glu-
cose level and aortic crossclamp time was 0.39 for nondi-
abetic and 0.28 for diabetic patients.
Discussion
The current study demonstrates that peak hyperglycemia
during CPB is associated with poor outcome after cardiac
TABLE 4. Glucose as an independent predictor of outcome
in patients with diabetes mellitus
Outcome variable
Odds
ratio
Lower
95% CI
Upper
95% CI P value
Mortality 1.20 1.08 1.32 .0005
Adverse cardiac events NS NS NS
All adverse events 1.04 1.00 1.08 .0378
Values represent odds ratios and 95% confidence intervals for 1 mmol/L
changes in serum glucose levels. Adverse cardiac events: myocardial
infarction, low output syndrome, death. All adverse events: stroke, infec-
tion, myocardial infarction, low output syndrome, death. CI, Confidence
interval; NS, not significant.
Figure 2. Highest serum glucose level during cardiopulmonary
bypass (CPB) as a function of the duration of cardiopulmonary
bypass in nondiabetic patients (n  6280; Spearman correlation
coefficient, r  0.43). Note that 25 mmol/L (450 mg/dL) is the
highest value the glucose analyzer displays. Thus a value of 25
mmol/L might reflect an even higher glucose level.
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and nondiabetic patients.
Perioperative hyperglycemia in the absence of exces-
sive glucose infusion might be caused by either impaired
insulin signaling at the target organs (ie, insulin resis-
tance) or inhibition of pancreatic insulin secretion. Al-
though we cannot provide information on insulin secre-
tion for the patients in this study, we demonstrated before
that the plasma C-peptide levels (reflecting endogenous
insulin secretion) for patients undergoing cardiac surgery
with the use of CPB and cardioplegic arrest remained
unaltered throughout the surgical procedures.1 These re-
sults strongly suggest that insulin secretion is not im-
paired during cardiac surgery. In addition, the inability of
the insulin bolus infusions given to patients with serum
glucose levels of greater than 15 mmol/L to avoid peak
glucose levels of greater than 20 mmol/L suggests an
impairment of the insulin signaling cascades in target
organs. Finally, some patients required inotropes to be
weaned from CPB, which might have affected glucose
levels. However, comparison of the peak glucose levels
of patients coming off bypass with inotropes versus with-
out inotropes revealed no difference. We therefore sug-
gest that hyperglycemia during CPB reflects a state of
insulin resistance that develops during surgical interven-
tion and that might contribute to poor outcome.
Currently, the adverse effects of hyperglycemia are most
convincingly demonstrated in patients having a stroke.10,11
Similar adverse relationships begin to emerge for patients
with acute myocardial infarction and those undergoing car-
diac surgery.12-14 Furnary and colleagues4 demonstrated a
direct relationship between postoperative glucose levels and
mortality in patients with DM. Although the results of these
studies are intriguing, 2 potentially confounding factors
make their interpretation difficult. First, postoperative se-
rum glucose levels in diabetic patients might be a reflection
of the severity of their disease, which might be an indicator
for more comorbidities and greater insulin resistance.7 Sec-
ond, patients with poor outcome are more likely to receive
more glucogenic drugs (eg, epinephrine) than patients with
an uncomplicated course and will therefore have higher
postoperative glucose levels. The latter argument might be
less applicable to the study by Furnary and colleagues4
because hyperglycemia was a significant predictor of mor-
tality independent of epinephrine and inotrope use, which
were both included in their analysis. Nevertheless, to min-
imize these potential confounding factors, we decided to
examine the relationship between intraoperative peak serum
glucose level, rather than postoperative glucose level, on
adverse outcomes.
From a treatment standpoint, van den Berghe and asso-
ciates6 and Lazar and coworkers5 provide the most convinc-
ing evidence to date that the establishment of postoperative
1144.e5 The Journal of Thoracic and Cardiovascular Surgery ● Oeuglycemia reduces morbidity and mortality. Van den
Berghe and associates6 randomized 1548 surgical ICU pa-
tients, of which 63% had undergone cardiac surgery, to
receive intensive insulin therapy versus conventional ther-
apy for hyperglycemia. Insulin therapy resulted in a one-
third reduction in serum glucose levels and lowered mor-
tality from 8.0% to 4.6% (P .04). The mortality reduction
was most notable in those patients who required an ex-
tended stay in the ICU (ie, 5 days). Lazar and coworkers5
randomized 141 diabetic patients and avoided hyperglyce-
mia in the treatment group by using a modified glucose-
insulin-potassium (GIK) protocol. These investigators dem-
onstrated less atrial fibrillation and a shorter length of stay
in the hospital and fewer recurrent ischemic events in the
follow-up period in the GIK-treated patients. These patients
also had lower glucose levels than control subjects. In
contrast, there are several reports demonstrating improved
cardiac outcomes with systemic GIK infusions, despite the
fact that these solutions resulted in hyperglycemia.1,15 Thus
it is still not clear whether hyperglycemia is a risk factor in
itself and whether its effect is the same in diabetic and
nondiabetic patients.
Hyperglycemia might be linked to adverse outcome
through direct or indirect mechanisms. Hyperglycemia in-
terferes with monocyte and neutrophil function, affects en-
dothelial function, and induces the expression of proinflam-
matory cytokines.16-18 These events might be responsible
for a directly negative effect of hyperglycemia, including
the facilitation of wound infection or sepsis with or without
multiorgan failure.6,13 Indirectly, hyperglycemia might be a
surrogate parameter for insulin resistance. Chronic insulin
resistance is considered to be a risk factor for coronary
artery disease, left ventricular hypertrophy, and diabetic
cardiomyopathy.14,19 The potential mechanisms for these
associations include the inhibition of the insulin signaling
cascade by free fatty acids20 or by inflammatory cytokines,
such as TNF-.21 Insulin resistance during surgical inter-
vention is thought to be caused by endogenous release of
catecholamines and cortisone as part of the body’s stress
response.22 However, it is reasonable to assume that the
mechanisms behind chronic insulin resistance also apply to
the acute setting. Heparin, administered before the com-
mencement of CPB, causes a drastic and sudden increase in
circulating free fatty acids,23 and the use of CPB is linked to
a massive production of inflammatory cytokines, including
TNF-.24 Thus it might be hypothesized that an acute
impairment of certain pathways of the insulin signaling
network could affect outcome.
We analyzed the effect of peak glucose levels during
CPB on postoperative morbidity and mortality in both dia-
betic and nondiabetic patients. We measured glucose levels
during CPB because they are not influenced by the admin-
istration of post-CPB glucogenic drugs. There was no sig-
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onary artery bypass grafting, valve with or without coronary
artery bypass grafting, and other procedures) and peak glu-
cose level. It is therefore reasonable to conclude that peak
glucose level during CPB is not a surrogate parameter for
the effects of a certain intervention or procedure but is more
likely to reflect the activation of endogenous mechanisms
leading to the clinical picture of insulin resistance.
The presence of such new-onset insulin resistance or the
aggravation of chronic insulin resistance during CPB is
supported by our analysis in several ways. First, many
diabetic and nondiabetic patients reached peak glucose lev-
els of greater than 20 mmol/L, even though insulin boluses
were administered when glucose levels exceeded 15
mmol/L. Second, nearly all patients undergoing cardiac
surgery had at least mild increases of serum glucose levels
(9.0 mmol/L) during CPB, a finding that has been de-
scribed by several other investigators.1,8,25 Third, insulin
secretion from the pancreas during CPB does not appear to
be impaired.1 Finally, the relationship between peak glucose
level and CPB and aortic crossclamp times (Figure 2) was
poor, suggesting that peak glucose level is not solely influ-
enced by the complexity of the operative procedure or the
amount of glucose-containing cardioplegia administered.
However, other factors might have influenced our find-
ings. Nondiabetic patients with peak glucose levels of
greater than 20 mmol/L had significantly more risk factors
(Table 1), suggesting that this patient population might have
experienced impaired insulin signaling before their opera-
tion. Unfortunately, we do not know the preoperative serum
glucose, circulating insulin, or HbA1c levels from our da-
tabase analysis and therefore cannot conclusively address
this issue. However, the percentage of patients with diabetes
in our study and our mode of arriving at the diagnosis is
similar to that presented in other studies in this field.5,6 We
also do not know in how many of the surviving nondiabetic
patients DM developed after the operation. However, the
same relationship between peak glucose level and mortality
existed in diabetic patients, in whom the risk profile was not
different in patients with and without severe (20 mmol/L)
hyperglycemia. Although it has to be considered that the
lack of different outcomes between diabetic and nondiabetic
patients might have been caused by the intravenous insulin
infusions administered to the diabetic patients, the multi-
variate analysis identified peak glucose level as an indepen-
dent predictor of death in both groups. We therefore hy-
pothesize that an impairment of (preoperative) insulin
sensitivity during surgical intervention might be associated
with poor outcome.
Several studies in the literature support our hypothesis
that insulin resistance might be the main cause for adverse
outcomes rather than the presence of hyperglycemia alone.
Booth and colleagues26 demonstrated that hyperglycemia
The Journal of Thoracic an(25 mmol/L) increases the rolling and adherence of leuko-
cytes in the mesenteric microvasculature of rats. The appli-
cation of physiologic doses of insulin without altering
glucose levels completely blocked these effects of hyper-
glycemia. Clinical support for our hypothesis can also be
obtained from several GIK cardiac surgery trials.8,27,28 In
these studies intravenous GIK is administered in the peri-
operative period, often resulting in very high levels of serum
glucose at supraphysiologic levels of circulating insulin.15
The GIK studies report normal or reduced rates of wound
infection and generally improved cardiac outcome, despite
the presence of hyperglycemia.8,29 Our hypothesis and the
GIK study findings are not contradictory with those studies
establishing a link between hyperglycemia and wound in-
fection because the groups with high glucose levels and
high rates of wound infection in those studies did not
receive larger doses of insulin.12,13 These findings support
the notion that impairment of the insulin signaling pathways
(ie, insulin resistance) might be an underlying cause for the
observed relationship between hyperglycemia and adverse
outcome. It might be hypothesized from our findings that
either exogenous hyperglycemia (as induced by many GIK
protocols) is less harmful or that the presence of insulin
during times of hyperglycemia is protective. Either way,
application of adequate dosages of insulin (which might be
high) should be recommended during postoperative hyper-
glycemia. The latter point is the most important conclusion
that can be made from the current study.
The current study demonstrates that peak hyperglycemia
during CPB is associated with adverse postoperative out-
comes in both diabetic and nondiabetic patients. We suggest
that hyperglycemia during CPB reflects a state of insulin
resistance developing during surgical intervention and that
this insulin resistance contributes to poor outcome, rather
than hyperglycemia alone. We speculate that the treatment
of insulin resistance might improve outcomes in all patients
undergoing cardiac surgery.
We thank Dale E. Abel, MD, DPhil, for advice and many
helpful suggestions.
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models.
Sex
Age
Left ventricular grade: left ventricular ejection fraction, as
assessed by means of angiography or 2-dimensional echocardiog-
raphy, where grade 1 is greater than 60%, grade 2 is 40% to 59%,
grade 3 is 20% to 39%, and grade 4 is less than 20%.
Recent (30 days) myocardial infarction
Timing: elective, semiurgent (operation during same hospital-
ization for cardiac event), urgent (operation 72 hours of cardiac
event), and emergency (operation 12 hours of cardiac event).
Canadian Cardiovascular Society Angina Class
New York Heart Association Heart Failure Class
Congestive heart failure: history of hospital admission for
congestive heart failure.
Shock: requirement for preoperative inotropes
Renal failure: serum creatinine level greater than 200 mol/L
or history of renal failure.
Diabetes mellitus: history of type I or type II diabetes mellitus
Hypertension
Hypercholesterolemia
The Journal of Thoracic anChronic obstructive pulmonary disease
Peripheral vascular disease: history of peripheral or carotid
vascular disease
Previous stroke or transient ischemic attack
History of syncope
Type of procedure: coronary bypass, valve with or without
coronary bypass, or other procedure (including heart transplant,
aneurysmectomy, ascending aortic replacement)
Prior cardiac operation
Prior coronary artery bypass grafting
Cardiopulmonary bypass time
Aortic crossclamp time
Cardiopulmonary bypass temperature
Cardioplegia temperature
Cardioplegia delivery: antegrade, retrograde, or combined (an-
tegrade and retrograde) cardioplegia
Number of diseased vessels
Number of bypass grafts
Use of left internal thoracic artery
Use of multiple arterial conduits
Highest and lowest glucose level during cardiopulmonarybypass
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